Black Diamond Therapeutics, Inc. Forecasted to Post Q3 2023 Earnings of ($0.65) Per Share (NASDAQ:BDTX)

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Get Rating) – Investment analysts at HC Wainwright issued their Q3 2023 EPS estimates for shares of Black Diamond Therapeutics in a research note issued to investors on Tuesday, March 14th. HC Wainwright analyst R. Burns expects that the company will earn ($0.65) per share for the quarter. The consensus estimate for Black Diamond Therapeutics’ current full-year earnings is ($1.76) per share. HC Wainwright also issued estimates for Black Diamond Therapeutics’ Q4 2023 earnings at ($0.67) EPS and FY2023 earnings at ($2.56) EPS.

Black Diamond Therapeutics Price Performance

BDTX opened at $1.67 on Thursday. The company has a 50 day simple moving average of $2.44 and a two-hundred day simple moving average of $2.16. The firm has a market cap of $60.92 million, a P/E ratio of -0.66 and a beta of 1.86. Black Diamond Therapeutics has a 1-year low of $1.18 and a 1-year high of $4.08.

Institutional Investors Weigh In On Black Diamond Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Beacon Capital Management LLC raised its position in shares of Black Diamond Therapeutics by 48.4% during the third quarter. Beacon Capital Management LLC now owns 35,615 shares of the company’s stock valued at $88,000 after buying an additional 11,615 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund grew its stake in Black Diamond Therapeutics by 376.1% during the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 357,100 shares of the company’s stock valued at $989,000 after acquiring an additional 282,100 shares in the last quarter. Millennium Management LLC increased its holdings in Black Diamond Therapeutics by 51.2% in the 4th quarter. Millennium Management LLC now owns 524,557 shares of the company’s stock valued at $944,000 after acquiring an additional 177,577 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Black Diamond Therapeutics by 31.8% in the 1st quarter. JPMorgan Chase & Co. now owns 260,472 shares of the company’s stock worth $723,000 after purchasing an additional 62,877 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Black Diamond Therapeutics by 2.8% in the 2nd quarter. Renaissance Technologies LLC now owns 272,002 shares of the company’s stock worth $669,000 after purchasing an additional 7,511 shares in the last quarter. 59.10% of the stock is owned by institutional investors.

Black Diamond Therapeutics Company Profile

(Get Rating)

Black Diamond Therapeutics, Inc, a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations.